BREAST CANCER RES:通过多种Omic方法分析乳腺癌细胞系的特征

2017-06-15 MedSci MedSci原创

乳腺癌细胞系经常被用作模型系统来研究乳腺癌的细胞特性和生物学。我们的目标是表征从美国典型培养物保藏中心(ATCC 30-4500 K)获得的一个大型常用的乳腺癌细胞系,使研究人员能够在选择细胞系进行特定研究时作出更明智的决定。首先,从各种来源获得关于这些细胞系的信息。 此外,生成了在每个细胞系内被激活的关于细胞途径的新信息。

背景:乳腺癌细胞系经常被用作模型系统来研究乳腺癌的细胞特性和生物学。我们的目标是表征从美国典型培养物保藏中心(ATCC 30-4500 K)获得的一个大型常用的乳腺癌细胞系,使研究人员能够在选择细胞系进行特定研究时作出更明智的决定。首先,从各种来源获得关于这些细胞系的信息。此外,生成了在每个细胞系内被激活的关于细胞途径的新信息。

方法:我们使用免疫印迹分析确定了关键的蛋白质表达数据。 此外,进行了关于血清饥饿细胞的两项分析以鉴定在这些细胞中被激活的细胞蛋白质和信号通路。这些分析使用商业的PathScan阵列和一种新颖且更广泛的基于磷酸肽的kinome分析来进行,该分析可以查询主要信号通路中的1290个磷酸化事件。关于这一组乳腺癌细胞系的数据也从几个在线来源获取,汇编和总结了以下领域:分子分类,mRNA表达,关键蛋白的突变状态和其他可能的癌症相关突变,以及在乳腺癌的小鼠异种移植模型中致瘤和转移能力。

结果:除4种非致瘤性乳腺细胞系外,我们表征的细胞系包括10个雌激素受体(ER)阳性,12个人表皮生长因子受体2(HER2)倍增和18个三阴性乳腺癌细胞系。在每个亚型中,存在显着的遗传异质性,可以影响模型细胞系的选择和所得结果的解释。这为哪些细胞系以常见或独特的方式进行调节,提供了进一步的清晰的了解。

原文出处:

Shari E.Smith,Scott Napper,Deborah H. Anderson,et al.Molecular characterization of breast cancer cell lines through multiple omic approaches.[J].Breast Cancer Research 2017. DOI: 10.1186/s13058-017-0855-0.

版权声明:本文系梅斯MedSci原创编译整理,未经本网站授权不得转载和使用。如需获取授权,请点击

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1647434, encodeId=adbf164e43486, content=<a href='/topic/show?id=8e43e1526b6' target=_blank style='color:#2F92EE;'>#癌细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71526, encryptionId=8e43e1526b6, topicName=癌细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4723405527, createdName=xjy10, createdTime=Mon May 21 16:45:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711077, encodeId=8b241e11077fe, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Sep 30 12:45:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252272, encodeId=83d612522e2b8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351091, encodeId=95121351091eb, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554009, encodeId=84541554009d7, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1647434, encodeId=adbf164e43486, content=<a href='/topic/show?id=8e43e1526b6' target=_blank style='color:#2F92EE;'>#癌细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71526, encryptionId=8e43e1526b6, topicName=癌细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4723405527, createdName=xjy10, createdTime=Mon May 21 16:45:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711077, encodeId=8b241e11077fe, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Sep 30 12:45:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252272, encodeId=83d612522e2b8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351091, encodeId=95121351091eb, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554009, encodeId=84541554009d7, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1647434, encodeId=adbf164e43486, content=<a href='/topic/show?id=8e43e1526b6' target=_blank style='color:#2F92EE;'>#癌细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71526, encryptionId=8e43e1526b6, topicName=癌细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4723405527, createdName=xjy10, createdTime=Mon May 21 16:45:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711077, encodeId=8b241e11077fe, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Sep 30 12:45:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252272, encodeId=83d612522e2b8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351091, encodeId=95121351091eb, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554009, encodeId=84541554009d7, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=1647434, encodeId=adbf164e43486, content=<a href='/topic/show?id=8e43e1526b6' target=_blank style='color:#2F92EE;'>#癌细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71526, encryptionId=8e43e1526b6, topicName=癌细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4723405527, createdName=xjy10, createdTime=Mon May 21 16:45:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711077, encodeId=8b241e11077fe, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Sep 30 12:45:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252272, encodeId=83d612522e2b8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351091, encodeId=95121351091eb, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554009, encodeId=84541554009d7, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1647434, encodeId=adbf164e43486, content=<a href='/topic/show?id=8e43e1526b6' target=_blank style='color:#2F92EE;'>#癌细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71526, encryptionId=8e43e1526b6, topicName=癌细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4723405527, createdName=xjy10, createdTime=Mon May 21 16:45:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711077, encodeId=8b241e11077fe, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sat Sep 30 12:45:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252272, encodeId=83d612522e2b8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351091, encodeId=95121351091eb, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554009, encodeId=84541554009d7, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Sat Jun 17 10:45:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]

相关资讯

Oncogenesis:科学家发现抑制乳腺癌肿瘤生长的神奇蛋白质

伯明翰大学的研究人员发现,一种蛋白质可以抑制乳腺癌肿瘤的生长。 最新研究表明脯氨酸富集同源异型域蛋白(PRH)在乳腺癌肿瘤发展中发挥的作用,进而有助于更好地确定患者的预后效果。

BMJ:什么才是乳腺癌患者术后淋巴水肿的更佳保守干预措施?

淋巴水肿是乳腺癌术后的常见并发症,但外科干预措施应用并不广泛,且仅作为重症淋巴水肿的治疗手段,因此临床上常使用保守干预措施。那么,最佳保守干预措施是什么?近期,荷兰癌症研究所理疗科的临诊流行病学家Martijn M Stuiver副教授发表在《BMJ》杂志上的一项研究对此进行了综述。

SCI REP:TRPC5诱导的自噬通过CaMKKβ/AMPKα/ mTOR途径促进乳腺癌中的耐药性

阿霉素是一种针对癌症的一线化疗药物,但抗药性的发展已成为一个主要问题。虽然自噬被认为是对化学疗法的适应性生存反应,并且可能与化学耐药性相关,但其诱导剂和潜在的分子机制仍不清楚。在这项研究中,我们证明阿霉素上调了TRPC5的表达和自噬的水平,并且,在乳腺癌细胞中,自噬的增加是由TRPC5介导的。

Oncogenesis:科学家发现抑制肿瘤生长的神奇蛋白质

伯明翰大学的研究人员发现,一种蛋白质可以抑制乳腺癌肿瘤的生长。今天发表在《肿瘤起源》上的这项研究,研究了脯氨酸富集同源异型域蛋白(PRH)在乳腺癌肿瘤发展中发挥的作用,进而有助于更好地确定患者的预后效果。伯明翰大学癌症与基因组学研究所的 Padma Sheela Jayaraman 博士说:“PRH 是一种控制和调节基因何时开启或关闭的蛋白质。”“然而,在我们的研究之前,这种蛋白质在乳腺癌中的作用

Science Translational Medicine-双拳出击-免疫检查点抑制治疗乳腺癌取得突破进展

免疫检查点抑制疗法作为一种新型的癌症治疗方法,对多种癌症有着显着的疗效。但是目前为止,并没有在乳腺癌领域取得显着的成效。近日,发表在《科学》杂志子刊 Science Translational Medicine上的封面文章采取新的组合疗法策略,对抑制肿瘤生长,提高小鼠生存率有明显作用。

JCO:晚期乳腺癌的患者的治疗--氟维司群+Abemaciclib,有效且安全(MONARCH 2研究)

MONARCH 2临床试验旨在对比 Abemaciclib 联合氟维司群与安慰剂联合氟维司群用于治疗激素受体阳性(HR+)、人体表皮生长因子受体2-阴性(HER2-)的局部晚期或转移性乳腺癌的治疗效果。Abemaciclib是一种选择性细胞周期蛋白依赖性激酶(CDK)4/6抑制剂。MONARCH 2是一个全球性的、双盲的III期临床试验,患者均为激素受体阳性(HR+)、人体表皮生长因子受体2-阴性